Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Laurence Zitvogel, Lorenzo Galluzzi, Mark J Smyth...
https://pubmed.ncbi.nlm.nih.gov/23890065/Actively Recruiting
Led by Gruppo Oncologico Italiano di Ricerca Clinica · Updated on 2025-03-13
142
Participants Needed
25
Research Sites
39 weeks
Total Duration
Researchers are evaluating if a combination of atezolizumab and standard chemotherapy can improve treatment outcomes for patients with sensitive relapse Extensive-stage Small Cell Lung Cancer ES-SCLC who have progressed after first-line treatment with platinum-etoposide chemotherapy plus PD-L1 inhibitors like atezolizumab or durvalumab. This phase II trial is designed to find out if continuing PD-L1 inhibition along with rechallenge chemotherapy increases overall survival and to monitor medical problems participants may experience. Eligible patients receive induction treatment with atezolizumab 1200 mg given intravenously on day 1 every 3 weeks along with carboplatin and etoposide chemotherapy for up to 4 cycles. After induction, patients continue maintenance therapy with atezolizumab every 3 weeks for up to 18 cycles or one year. Treatment continues until disease progression, unacceptable side effects, patient choice, or loss of clinical benefit. The study spans an expected 45 months, including 24 months for recruitment, 15 months maximum treatment duration, and up to 6 months of follow-up. Participants visit the clinic every 3 weeks for treatment, checkups, and tests. Radiological assessments using CT scans are done at 6 weeks, 12 weeks, and then every 12 weeks to check treatment response. Researchers continuously monitor safety and adverse events during treatment. The primary outcome is overall survival over about one year, with additional measures including progression-free survival and the frequency of adverse events. Participants are closely observed throughout the study to evaluate treatment effects and safety.
CONDITIONS
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
A
Andrea Ardizzoni, MD
G
Giuseppe Lamberti, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Gruppo Oncologico Italiano di Ricerca Clinica
Lead Sponsor
Roche Pharma AG
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 months (3 months induction and 12 months maintenance)
Participants receive re-challenge chemotherapy combined with atezolizumab. This includes an induction phase of up to 4 cycles followed by a maintenance phase with atezolizumab alone.
Clinical visits every 3 weeks for treatment administration and assessments
Duration - Up to 6 months
Participants are monitored for safety and survival outcomes after treatment completion.
Regular follow-up visits for safety and survival assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Laurence Zitvogel, Lorenzo Galluzzi, Mark J Smyth...
https://pubmed.ncbi.nlm.nih.gov/23890065/Sen Yang, Zhe Zhang, Qiming Wang
https://pubmed.ncbi.nlm.nih.gov/31046803/Stephen V Liu, Martin Reck, Aaron S Mansfield...
https://pubmed.ncbi.nlm.nih.gov/33439693/Andrea Ardizzoni, Marcello Tiseo, Luca Boni
https://pubmed.ncbi.nlm.nih.gov/24981975/Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen...
https://pubmed.ncbi.nlm.nih.gov/31590988/Lingling Li, Tingting Liu, Qingyan Liu...
https://pubmed.ncbi.nlm.nih.gov/36147357/A S Mansfield, A Każarnowicz, N Karaseva...
https://pubmed.ncbi.nlm.nih.gov/31959349/Francesco Spagnolo, Andrea Boutros, Federica Cecchi...
https://pubmed.ncbi.nlm.nih.gov/33865350/A-M C Dingemans, M Früh, A Ardizzoni...
https://pubmed.ncbi.nlm.nih.gov/33864941/Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna...
https://pubmed.ncbi.nlm.nih.gov/30280641/Gruppo Oncologico Italiano di Ricerca Clinica
Lead Sponsor
Roche Pharma AG
Collaborating Sponsor